Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Malaria-Fighting drug given to entire villages shows promise

NCT ID NCT06575647

Disease control Sponsor: Shoklo Malaria Research Unit Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested giving a single dose of the drug tafenoquine to everyone in three villages in Myanmar to see if it could safely stop the spread of P. vivax malaria. Over 1,200 people took part, and researchers tracked side effects and malaria cases for six months. The goal was to see if this approach could prevent malaria from coming back after regular control programs were disrupted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tafenoquine (a single-dose malaria drug)
What this could lead to
If successful, this approach could help eliminate malaria in hard-to-reach areas by stopping the parasite from spreading.
What could go wrong
This is a completed Phase 4 study focused on safety and feasibility, not proof of long-term elimination. Political and logistical challenges in the region may limit broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

1,242 people

The number who actually took part.

Started

Feb 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All village residence, aged \>6 months who agrees to participate in the research. Exclusion Criteria: * People who refuse to participate * People who are hypersensitive to Tafenoquine or Chloroquine * Critically ill patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malaria Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malaria Malaria vivax Plasmodium vivax Plasmodium vivax malaria

Contacts and locations

Locations

  • Shoklo Malaria Research Unit (SMRU)

    Mae Sot, Changwat Tak, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.